Introduction
============

Leptomeningeal metastases (LM) are a relatively rare but fatal complication. The quality of life (QOL) of patients with LM is reduced significantly. The incidences of LM reported for solid cancers and for non-small-cell lung cancer (NSCLC) are 5% and 1%, respectively.[@b1-ott-9-1753] Recently, the frequency of LM in NSCLC patients harboring epidermal growth factor receptor (EGFR) mutations has increased, because the use of EGFR tyrosine kinase inhibitors (TKIs) has prolonged patient survival.[@b2-ott-9-1753] However, the efficacies of standard treatments for LM, including systemic chemotherapy, intrathecal chemotherapy, and whole-brain radiotherapy (WBRT), has room for improvement.[@b2-ott-9-1753]--[@b4-ott-9-1753] In patients with LM due to NSCLC harboring EGFR mutations, the survival prognoses average 5.3 months, even with EGFR-TKI treatment,[@b5-ott-9-1753] and this is not satisfactory. We report here the case of a patient with LM who with multimodal treatment (including EGFR-TKIs, ventriculoperitoneal \[VP\] shunt placement, WBRT, and bevacizumab) recovered substantial QOL and survived 10 months after her initial diagnosis.

Case
====

A 54-year-old Japanese woman was diagnosed with lung adenocarcinoma harboring an EGFR exon 21 L858R point mutation. Her clinical stage was T2aN0M1b, stage IV with multiple bone metastases and pleural dissemination ([Figure 1](#f1-ott-9-1753){ref-type="fig"}). Gadolinium-enhanced MRI of the head demonstrated no specific findings.

Okayama university Institutional Review board does not require institutional review for case reports. This patient's family gave written informed consent to publish this report, and the identity of the patient has been protected.

The patient was treated with gefitinib (250 mg/d), and her primary tumor shrunk 80% in its longest diameter (a response evaluation criterion for solid tumors); her pleural effusion was slightly reduced. No unexpected adverse events were observed. Approximately 2 months after the initiation of gefitinib, a gait disorder and impaired cognition were noted, and the patient's performance status (PS) decreased from 1 to 3. Gadolinium-enhanced MRI of the head showed hydrocephalus without parenchymal metastases ([Figure 2](#f2-ott-9-1753){ref-type="fig"}). Tests on cerebrospinal fluid (CSF) demonstrated elevated opening pressure (270 mmH~2~O), and cytology revealed adenocarcinoma cells. The patient was switched to erlotinib (150 mg/d) from gefitinib, and her symptoms were improved temporarily. The patient's pleural effusion disappeared without significant adverse events other than a grade 1 skin rash. Her symptoms were recrudescent after 3 months. A computed tomography (CT) scan of the head demonstrated that the hydrocephalus had worsened ([Figure 3A](#f3-ott-9-1753){ref-type="fig"}). Its rapid progression left the patient in a deep coma, with a Glasgow Coma Scale score of 3, and her life in danger.

Since all extracranial lesions remained responsive, and the exon 20 T790M point mutation was not detected in cerebrospinal fluid, we determined that ventricular drainage and subsequent placement of a VP shunt might be an effective treatment option for the patient. Emergency ventricular drainage and subsequent placement of a VP shunt were performed. The patient recovered without disturbed or impaired cognition. Her PS improved from 4 to 2, and she regained the ability to self-feed and to walk by herself. Although this treatment approach improved her hydrocephalus ([Figure 3B](#f3-ott-9-1753){ref-type="fig"}), complete blindness and a bilateral hearing disorder developed as a result of direct invasion of LM lesions into the relevant nerves. Gadolinium-enhanced MRI exhibited diffuse enhancement of the cranial dura mater. The optic canal and internal auditory canal were also enhanced ([Figure 4](#f4-ott-9-1753){ref-type="fig"}). Although the patient continued erlotinib treatment and WBRT was performed concurrently (2 Gy single and daily fractions for 5 consecutive days each week with a total dose of 30 Gy), the auditory disorder progressed slowly. After WBRT, the patient received systemic administration of bevacizumab (15 mg/kg every 3 weeks) in addition to erlotinib (150 mg/d). Three cycles of bevacizumab improved the patient's auditory disorder slightly and improved her vision impairment from complete blindness to counting fingers. She continued bevacizumab for up to seven cycles without the development of carcinomatous peritonitis, and there were no severe toxicities noted, other than the grade 1 skin rash.

The patient's cranial nerve palsy progressed gradually. She died as a result of LM progression 10 months after the initial diagnosis ([Figure 5](#f5-ott-9-1753){ref-type="fig"}).

Discussion
==========

Recently, several studies have reported combination therapy with EGFR-TKIs and bevacizumab for NSCLC patients ([Table 1](#t1-ott-9-1753){ref-type="table"}).[@b6-ott-9-1753],[@b7-ott-9-1753] However, to the best of our knowledge, this is the first case report of combination treatment with EGFR-TKI and bevacizumab used for LM due to NSCLC. LM is the dissemination of malignant tumor cells through the CSF space. The infiltration of these spreading tumor cells to arachnoid villi and cranial nerves leads to hydrocephalus, cranial nerve palsy, and deterioration of the PS. Progression of hydrocephalus is often fatal. Recently, several studies have reported that EGFR-TKIs, especially erlotinib compared with gefitinib, might be effective treatments for LM in NSCLC with EGFR mutations.[@b5-ott-9-1753],[@b8-ott-9-1753]--[@b10-ott-9-1753] However, in some cases (including that of the patient presented here), the efficacy of EGFR-TKI was not sustained because the intracranial disease could not be controlled sufficiently. One reason for this is that, when used at a standard dose, the concentration of EGFR-TKIs in CSF is unable to reach therapeutic levels.[@b9-ott-9-1753],[@b11-ott-9-1753] Togashi et al[@b12-ott-9-1753] reported that the penetration rates of gefitinib and erlotinib were 1.13%±0.36% and 2.77%±0.45%, respectively. A VP shunt has been reported to be an effective and palliative treatment for malignant hydrocephalus.[@b13-ott-9-1753],[@b14-ott-9-1753] In addition, the combination of a VP shunt and EGFR-TKIs, to maintain an adequate antitumor effect against malignant cells, could reduce fatalities caused by hydrocephalus, without leading to the development of carcinomatous peritonitis.[@b15-ott-9-1753]--[@b17-ott-9-1753] Although this combination therapy was effective for improving symptoms caused by hydrocephalus, cranial nerve palsy caused by direct invasion of LM was not controlled. Therefore, additional treatment remained necessary in this situation.

Bevacizumab may be an attractive option for obtaining adequate tumor regression. Several studies have reported that vascular endothelial growth factor (VEGF) levels in the CSF of patients with LM were at least 14-fold higher than those seen in patients with other neurological disorders. Furthermore, elevated VEGF in the CSF was a strong predictor of poor survival.[@b18-ott-9-1753],[@b19-ott-9-1753] This evidence suggests that the VEGF signal can affect the development and progression of LM. Seto et al[@b7-ott-9-1753] reported that erlotinib in combination with bevacizumab significantly prolonged the survival of patients with NSCLC harboring EGFR mutations. In addition, our group reported[@b6-ott-9-1753] that gefitinib in combination with bevacizumab is an effective treatment for these NSCLC patients. Moreover, a Phase II prospective study indicated encouraging efficacy of bevacizumab for NSCLC with asymptomatic brain metastases. In that study, the response rate to bevacizumab with chemotherapy for brain metastases was 61.2%, with a median duration of 8.1 months.[@b20-ott-9-1753] One of the reasons suggested for this efficacy is that antiangiogenic agents increase the intratumoral concentration of antitumor drugs.[@b21-ott-9-1753]--[@b23-ott-9-1753]

Although there is no evidence that bevacizumab can enter the CSF, these results suggest that even with the blood--brain barrier, bevacizumab can be effective against tumor cells that have invaded the brain parenchyma or dura mater in patients with LM. On the other hand, bevacizumab might not be as effective against the floating tumor cells found in CSF. In our strategy, the VP shunt discharged these tumor cells into the peritoneal cavity, where most chemotherapeutic agents can be delivered.

In addition, for this case, the mechanism by which bevacizumab exerted additional effects might be through a reduction in cerebral edema secondary to WBRT.[@b24-ott-9-1753],[@b25-ott-9-1753] A pilot study evaluating the efficacy of systemically administered bevacizumab in patients with neoplastic meningitis is ongoing (NCT00924820), and we expect this study to address whether bevacizumab is an effective treatment for LM.

In conclusion, the combination of erlotinib and a VP shunt was effective for hydrocephalus, and a multimodal treatment, including WBRT and bevacizumab, improved survival and QOL in a case of LM resulting from lung cancer harboring an EGFR mutation. The most important strategy in preventing LM-related cranial nerve palsy is the administration of adequate additional antitumor treatment as soon as symptoms occur after placement of a VP shunt.
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![Radiological findings observed on initial visit.\
**Notes:** (**A**) Chest radiograph revealed right pleural effusion. (**B**) Chest computed tomography revealed a mass in segment 6 of the right lower lobe.](ott-9-1753Fig1){#f1-ott-9-1753}

![Gadolinium-enhanced MRI of the head on day 48 after the initiation of gefitinib.\
**Note:** Hydrocephalus was detected without intracranial metastases.](ott-9-1753Fig2){#f2-ott-9-1753}

![Radiological findings before and after VP shunt placement.\
**Notes:** (**A**) Hydrocephalus on the head CT had worsened compared with the head MRI performed before the initiation of erlotinib. A low-density area was observed in the white matter of the bilateral frontal lobe because of intracranial hypertension 3 months after switching from gefitinib to erlotinib. (**B**) A head CT after VP shunt placement indicated that the malignant hydrocephalus had improved.\
**Abbreviations:** VP shunt, ventriculoperitoneal shunt; CT, computed tomography.](ott-9-1753Fig3){#f3-ott-9-1753}

![Gadolinium-enhanced MRI of the head after emergency placement of the VP shunt.\
**Notes:** Gadolinium-enhanced MRI showed diffuse enhancement of the cranial dura mater. No evidence of brain parenchymal metastases was observed. (**A**) Thickening and enhancement of the dura mater in the optic nerve canal were observed (white arrows). (**B**) Thickening and enhancement of the dura mater in the auditory nerve canal were observed (white arrows).\
**Abbreviation:** VP shunt, ventriculoperitoneal shunt.](ott-9-1753Fig4){#f4-ott-9-1753}

![The clinical course of this patient.\
**Abbreviations:** G, gefitinib; E, erlotinib; Bev, bevacizumab; WBRT, whole-brain radiotherapy; VP shunt, ventriculoperitoneal shunt; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LM, leptomeningeal metastases.](ott-9-1753Fig5){#f5-ott-9-1753}

###### 

The review of literature summarizing the clinical data on the combination of EGFR-TKIs and bevacizumab for non-small-cell lung cancer harboring an EGFR mutation

                           JO025567   OLCSG1001   
  ------------------------ ---------- ----------- ----
  EGFR mutation type                              
   Ex 19 del (%)           52         53          57
   L858R (%)               48         47          38
   Others (%)              0          5           0
  ORR (%)                  63         69          74
  Median PFS (months)      10         16          14
  AE                                              
   Grade 3--4 (%) AEs      51         91          60
   Rash (%)                19         25          15
   Diarrhea (%)            1          1           
   Hypertension (%)        10         60          17
   Proteinuria (%)         8          0           7
   Hemorrhagic event (%)   0          3           2

**Note:** Data from references.[@b6-ott-9-1753],[@b7-ott-9-1753]

**Abbreviations:** EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; Bev, bevacizumab; Ex, exon; del, deletion; ORR, objective response rate; PFS, progression-free survival; AE, adverse event; OS, overall survival.
